Digest Réseau Comment ça marche
Réseau
/
Sociétés
No
Non vérifié

Novartis Pharma AG

Ce que nous écrivons

Annonces ÉconomiquesIndustrie pharmaceutiqueManagement/Organisation d'EntrepriseMédecine Santé Bien-êtrePublicité/Marketing/Médias/Communication

116 communiqués de presse

Voir tous les communiqués de presse
18/09/2026
Industrie pharmaceutique
Annonces Économiques
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
Source
Novartis Pharma AG
Émetteur
GLOBENEWSWIRE
1.00
0
07/09/2026
Industrie pharmaceutique
Annonces Économiques
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
Source
Novartis Pharma AG
Émetteur
GLOBENEWSWIRE
1.00
0
04/09/2026
Industrie pharmaceutique
Annonces Économiques
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Source
Novartis Pharma AG
Émetteur
GLOBENEWSWIRE
1.00
0
31/08/2026
Industrie pharmaceutique
Annonces Économiques
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
Source
Novartis Pharma AG
Émetteur
GLOBENEWSWIRE
1.00
0
18/08/2026
Industrie pharmaceutique
Annonces Économiques
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Source
Novartis Pharma AG
Émetteur
GLOBENEWSWIRE
1.00
0
31/07/2026
Industrie pharmaceutique
Annonces Économiques
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Source
Novartis Pharma AG
Émetteur
GLOBENEWSWIRE
1.00
0
20/07/2026
Industrie pharmaceutique
Management/Organisation d'Entreprise
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
Source
Novartis Pharma AG
Émetteur
GLOBENEWSWIRE
1.00
0
16/07/2026
Industrie pharmaceutique
Annonces Économiques
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Source
Novartis Pharma AG
Émetteur
GLOBENEWSWIRE
1.00
0
05/07/2026
Industrie pharmaceutique
Annonces Économiques
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
Source
Novartis Pharma AG
Émetteur
GLOBENEWSWIRE
1.00
0
01/07/2026
Industrie pharmaceutique
Annonces Économiques
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Source
Novartis Pharma AG
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0